Development and clinical implementation of a digital system for risk assessments for radiation therapy.

Autor: Kornek D; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: dominik.kornek@uk-erlangen.de., Menichelli D; IBA Dosimetry GmbH, 90592 Schwarzenbruck, Germany. Electronic address: David.Menichelli@iba-group.com., Leske J; IBA Dosimetry GmbH, 90592 Schwarzenbruck, Germany. Electronic address: Joerg.Leske@iba-group.com., Hofmann M; IBA Dosimetry GmbH, 90592 Schwarzenbruck, Germany. Electronic address: Michael.Hofmann@iba-group.com., Antkiewicz D; IBA Dosimetry GmbH, 90592 Schwarzenbruck, Germany. Electronic address: David.Antkiewicz@iba-group.com., Brandt T; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: Tobias.Brandt@uk-erlangen.de., Ott OJ; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: Oliver.Ott@uk-erlangen.de., Lotter M; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: Michael.Lotter@uk-erlangen.de., Lang-Welzenbach M; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: Marga.Lang-Welzenbach@uk-erlangen.de., Fietkau R; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: Rainer.Fietkau@uk-erlangen.de., Bert C; Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. Electronic address: Christoph.Bert@uk-erlangen.de.
Jazyk: angličtina
Zdroj: Zeitschrift fur medizinische Physik [Z Med Phys] 2024 Aug; Vol. 34 (3), pp. 371-383. Date of Electronic Publication: 2023 Sep 02.
DOI: 10.1016/j.zemedi.2023.08.003
Abstrakt: Before introducing new treatment techniques, an investigation of hazards due to unintentional radiation exposures is a reasonable activity for proactively increasing patient safety. As dedicated software is scarce, we developed a tool for risk assessment to design a quality management program based on best practice methods, i.e., process mapping, failure modes and effects analysis and fault tree analysis. Implemented as a web database application, a single dataset was used to describe the treatment process and its failure modes. The design of the system and dataset allowed failure modes to be represented both visually as fault trees and in a tabular form. Following the commissioning of the software for our department, previously conducted risk assessments were migrated to the new system after being fully re-assessed which revealed a shift in risk priorities. Furthermore, a weighting factor was investigated to bring risk levels of the migrated assessments into perspective. The compensation did not affect high priorities but did re-prioritize in the midrange of the ranking. We conclude that the tool is suitable to conduct multiple risk assessments and concomitantly keep track of the overall quality management activities.
Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The inventors with the Department of Radiation Oncology, Universitätsklinikum Erlangen, and IBA Dosimetry GmbH have a patent pending on some functionality of myQA® PROactive.
(Copyright © 2023 The Author(s). Published by Elsevier GmbH.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: